Abstract

Ischemia-reperfusion (I/R) injury initiates and exacerbates a series of oxidative and inflammatory events, and causes high morbidity and mortality. Despite the progress made with recent clinical use of anti-malarial drugs, the response rate of I/R injury treatment remains unsatisfactory. Here, we showed a neutrophil membrane-enveloped Coenzyme Q (N-NPCoQ10) nanoparticle strategy for I/R injury treatment. We validated the physicochemical and biological reproducibility of the nanoparticles and tested the protective effects of N-NPCoQ10 in oxygen-glucose deprivation/reperfusion model and renal I/R injury mouse model. N-NPCoQ10 nanoparticles administration exhibited synergistic protective effect against I/R injury, which significantly reduced oxidative damage in vitro and in vivo, inhibited renal cell apoptosis, attenuated inflammatory response in renal I/R injury model, and finally improved renal function of I/R injury mice. The N-NPCoQ10 nanoparticles administration provides an efficient way to deliver anti-oxidant that suppresses oxidative damages and neutralize proinflammatory cytokines during renal I/R injury, which might be a potential strategy for renal acute kidney injury treatment. Statement of SignificanceThe neutrophil membrane-enveloped Coenzyme Q nanoparticles (N-NPCoQ10) provides an efficient way to protect oxidative, inflammatory, and apoptotic reaction in renal I/R injury, which might be a potential strategy for renal acute kidney injury treatment.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.